Research Ethics Committee Reference Number	IRAS no	Full Name of Trial	Site Invitation date	Site selection date	HRA Approval date	Date site confirmed by Sponsor	Date site confirmed	Non-confirmation status (if applicable)	Date when site ready to start	Date of First Patient Recruited	Reasons for not achieving the 70 day target from receipt of valid research application to 1st patient recruited										Study team comments	Reasons for delay correspond to:
											A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other		
14/LO/0344	140294	A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease	22/03/2016	08/06/2016	08/06/2016	05/05/2016	06/05/2016														This study was caught up in the changeover to HRA approvals. We received notification of HRA approval on 8.6.16 and continued with our study set-up processes.	Neither
15/NI/0177	167436	IVAN FOLLOW UP: Five year observational follow-up of the IVAN trial cohort: a study of function and morphology	14/01/2016	22/06/2016	15/06/2016	02/02/2016	11/02/2016														The set-up of this study has been impacted by the Sponsor issuing an amendment during the introduction of HRA Approval, which meant HRA Approval had to awaited. Subsequent to this, the Sponsor is awaiting some outstanding documentation from the study team before the green light can be given.	Neither